Xuanzhu Biopharmaceutical Co., Ltd. announced on 12 May 2026 that it has finalised its H-share full-circulation programme, converting 357.25 million unlisted domestic shares into H shares. The newly converted shares will commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on 13 May 2026.

Prior to the conversion, unlisted shares represented 68.97% of Xuanzhu Biopharmaceutical’s issued share capital, while H shares accounted for 31.03%. Following the transaction, the company’s entire issued share capital of 517.95 million shares is now composed solely of H shares, fully aligning the share structure with Hong Kong’s public market.

Management cautions shareholders and potential investors to exercise due care when dealing in the company’s shares.